

May 25, 2021

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission

Dear Sir/Madam:

Re: BetterLife Pharma Inc.

We refer to the prospectus supplement of BetterLife Pharma Inc. (the "Company") dated May 25, 2021 relating to the issuance of units comprising common shares and common share purchase warrants with a total offering price of such securities of \$5,500,000.

We consent to being named and to the use, through incorporation by reference in the above-mentioned prospectus supplement to the short form base shelf prospectus dated April 26, 2021, of our report dated August 24, 2020, to the shareholders of Altum Pharmaceuticals Inc. on the following financial statements:

- a. Consolidated statements of financial position of Altum Pharmaceuticals Inc. as at March 31, 2020 and March 31, 2019; and,
- b. Consolidated statements of loss and comprehensive loss, consolidated statements of shareholders' equity and consolidated statements of cash flows and the notes to the consolidated financial statements of Altum Pharmaceuticals Inc. for each of the years in the two year period ended March 31, 2020 and March 31, 2019.

We report that we have read the prospectus supplement and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Sincerely,



MNP LLP

Chartered Professional Accountants